The COVID-19 pandemic has significantly impacted cervical cancer screening programs worldwide. According to several studies, there was a major drop in the number of cervical cancer screenings during the initial waves of the COVID-19 pandemic compared to the pre-pandemic period. For example, in Korea, screening rates declined by around 48% for cervical cancer during the first COVID-19 wave in March 2020 compared to the same period in 2019. In Canada, screening Pap tests and colposcopies decreased across the country, especially in private clinics. In England, two scenarios estimating the impact of COVID-19 disruptions on cervical cancer screening found that there could be between 630 to 632 excess cervical cancer cases over one screening cycle. A study in Brazil found that the median number of Pap tests done decreased by 56% in 2020 compared to 2019, with follow-up cytology evaluations also dropping by 44% during the same time period. The reductions in testing coincided with the increases in precancerous cervical lesions detected in 2020 and 2021 compared to 2019, indicating the potential for higher cervical cancer rates. In Germany, a severe decrease in the number of patients receiving cervical cancer screening was observed between 2018-2019 and 2020-2021, suggesting many underdiagnosed precancerous lesions and the possibility of higher future cervical cancer burden. While global health organizations have warned about the negative consequences of drops in cancer screening rates during the COVID-19 pandemic, some studies found limited or no significant changes. For example, a study of rural health clinics in the U.S. found that although cancer screening services declined during the pandemic, the rates of decline were not statistically significant. Another study found that cervical cancer screening rates at one medical center in Mississippi did not significantly change during the COVID-19 pandemic compared to pre-pandemic levels, though HPV testing rates did decrease. In summary, most studies have found that the COVID-19 pandemic has severely disrupted cervical cancer screening programs, with significant drops in screening and follow-up rates coinciding with the initial waves of the pandemic. These consequences could potentially lead to higher rates of undiagnosed precancerous lesions and greater cervical cancer burden. Targeted interventions and catch-up campaigns will likely be needed to restore screening coverage and address these impacts.